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OBJECTIVES To conduct a pilot study to investigate functional, metabolic, and penile morphologic changes
in a novel model of lean DM2. Erectile dysfunction (ED) is a frequent sequela in patients with
type 2 diabetes mellitus (DM2).
METHODS Eight rats received a high-fat diet and 2 weeks later, 2 intraperitoneal injections of streptozotocin
(STZ, 30 mg/kg). Five age-matched rats served as controls. Insulin challenge tests were per-
formed at 6 and 12 weeks after induction of DM2. At 12 weeks, erectile function was tested by
measurement of intracavernous pressure (ICP) increase upon cavernous nerve stimulation.
Penile tissue and serum samples were harvested for histology and biochemistry, respectively.
RESULTS A lean DM2model was established as demonstrated by decreased insulin resistance, elevated nonfast-
ing plasma glucose levels, hyperlipidemia, and decreased insulin concentration in the absence of
obesity. ICP/mean arterial pressure was significantly decreased in DM2 animals (0.29) compared with
controls (0.81). Expression of neuronal nitric oxide synthase and rat endothelial cell antigen-1, and
the smooth muscle/collagen ratio were significantly decreased in the penis of DM2 animals.
CONCLUSIONS We propose an inexpensive nongenetic animal model of lean DM2-associated ED. Microanat-
omical changes in the erectile tissue that reflect an advanced stage of the disease were
observed. UROLOGY 78: 476.e1–476.e8, 2011. © 2011 Elsevier Inc.
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dType 2 diabetes mellitus (DM2) constitutes a majorrisk factor for erectile dysfunction (ED). In arecent study, 3 of 5 men with DM2 lasting 6
months to 10 years suffered from ED and two thirds of
those had moderate or severe ED.1 Several studies have
concluded that ED in DM2 is associated with a hyper-
contractile state of the penile smooth muscle, an impair-
ment of endothelial function, and changes in collagen
and elastin metabolism, which together manifest as
symptoms of corporeal veno-occlusive dysfunction.2-7
However, most of these studies were conducted with
expensive genetic rat models of DM2 that reproduce
some but not all aspects of the natural disease progres-
sion.2-8 In a recent study, Chiou et al9 established a
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ombined with injection of low-dose streptozotocin
STZ). Independently, we have also developed a compa-
able DM2 model for ED research in which the develop-
ent of DM2 closely resembles the natural disease pro-
ression in humans. This novel model is inexpensive
ompared with the currently available genetic models, is
asy to establish, and has high success rates of diabetic
nduction.10 Furthermore, this model possesses a lean
henotype rather than the obese phenotype that charac-
erizes the commonly used genetic models while possess-
ng biochemical characteristics of the metabolic syn-
rome.10 The aim of our pilot study was to assess the
development of ED in this lean model of DM2, including
metabolic, hormonal, functional, and morphologic char-
acteristics.
MATERIAL AND METHODS
Study Design and
Induction of Type 2 Diabetes Mellitus
For this pilot study, 8 male Sprague-Dawley rats (12 weeks old)
were obtained from Charles River Laboratories (Wilmington,
MA) for induction of DM2 (DM2-group). Five age-matched
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mtermanimals served as nondiabetic controls (control-group). The
animals were maintained on a 12-hour light/dark cycle and had
access to water ad libitum. The experimental group was fed rat
chow containing 2% cholesterol and 10% lard (Zeigler Bros,
Gardners, PA). Two weeks later, rats in the DM2 group re-
ceived 2 intraperitoneal injections of streptozotocin (STZ, 30
mg/kg) 3 days apart, whereas the control rats were given vehicle
citrate buffer in a dose volume of 0.25 mL/kg, respectively.
Starting from the first day of STZ injection (week 0), postpran-
dial capillary blood glucose was monitored weekly by tail tip
snipping and measurement with an Accu-Chek advantage
blood glucose meter (Roche, Mannheim, Germany). An intra-
peritoneal insulin challenge test was conducted at 6 and 12
weeks after STZ injection. At 12 weeks after injection of STZ,
all rats underwent erectile function evaluation. The animals
were then sacrificed and the penis was harvested for histologic
analysis. Serum was collected for measurement of lipid, testos-
Figure 1. Growth curves, glucose metabolism, and serum
ental animals. Body weight was measured weekly startin
glucose levels were measured weekly starting at the day of
6 and 12 weeks after the first STZ injection. *P .05. (E) L
(F) Levels of insulin and total testosterone in rat serum deterone, and insulin levels. All animal experiments were ap-
476.e2proved by the Institutional Animal Care and Use Committee at
the University of California, San Francisco.
Intraperitoneal Insulin Challenge Test
For measurement of the sensitivity to a challenge of insulin, 1
IU/kg bovine insulin in phosphate-buffered solution (PBS) (1
IU/mL) was administered by intraperitoneal injection and tail
snip capillary blood samples were collected at 0, 15, 30, 45, 60,
90, and 120 minutes after injection for obtaining a blood
glucose response curve. The glucose levels are presented as
percentages of plasma glucose level before insulin injection
(baseline).
Assessment of Erectile Function
Twelve weeks after STZ injection, erectile function was as-
sessed. Under ketamine (100 mg/kg) and midazolam (5 mg/kg)
anesthesia, the major pelvic ganglion and the cavernous nerves
hemistry. (A) Graph depicts growth curves of the experi-
the day of the first STZ injection. (B) Postprandial blood
first STZ injection. (C, D) Insulin challenge test carried out
s of lipids on rat serum biochemistry evaluation. *P .05.
ined by enzyme-linked immunosorbent assay. *P .05.bioc
g at
the
evelwere exposed bilaterally via midline laparotomy. A 23G but-
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cterfly needle was inserted into the proximal left corpus caver-
nosum, filled with 250 U/mL heparin solution, and connected
to a pressure transducer (Utah Medical Products, Midvale, UT)
for intracavernous pressure (ICP) measurement. The ICP was
recorded at a rate of 10 samples/second using a computer with
LabVIEW 6.0 software (National Instruments, Austin, TX). A
bipolar stainless steel hook electrode was used to stimulate the
cavernous nerve (CN) directly (each pole 0.2 mm in diameter,
separated by 1 mm) via a signal generator (National Instru-
ments) generating monophasic rectangular pulses with stimulus
parameters of 1.5 mA, 20 Hz, pulse width 0.2 ms, and duration
50 seconds. Three stimulations were conducted per side and the
erection with maximum increase in ICP was included for sta-
tistical analysis in each animal. Systemic blood pressure was
recorded using a 23G butterfly needle inserted into the aorta at
the level of the aortic bifurcation, for the calculation of the ICP
increase/mean arterial pressure (MAP) ratio. Venous blood was
collected from the inferior vena cava before animals were
euthanized.
Serum Analysis
Venous blood was collected in mini-serum gel separator tubes
(BD Microtainer, Franklin Lakes, NJ) and centrifuged for 90
seconds at 15.000g. For analysis of the lipid panel, serum was
examined by the Comparative Pathology Laboratory of the
University of California, Davis School of Veterinary Medicine.
Testosterone (RD systems, Minneapolis, MN) and insulin (Mil-
lipore, Billerica, MA) levels were measured by enzyme-linked
immunosorbent assay according to the manufacturer’s instruc-
tions.
Histology
Midpenile tissue was harvested and fixed in cold 2% formalde-
hyde and 0.002% saturated picric acid in 0.1-M phosphate
buffer, pH 8.0, for 4 hours followed by overnight immersion in
buffer containing 30% sucrose. The specimens were then em-
bedded in OCT Compound (Sakura Finetec, Torrance, CA)
and stored at –80°C until use. Fixed frozen tissue specimens
were cut at 5 m, mounted onto SuperFrost-plus charged slides
(Fisher Scientific, Pittsburgh, PA), and air dried on a warm
plate for 5 minutes. For immunofluorescence staining, tissue
sections were placed in 4% paraformaldehyde for 10 minutes,
washed twice in PBS for 5 minutes and incubated with 3%
horse serum in PBS/0.3% Triton x-100 for 30 minutes at room
temperature. After draining the sections, the slides were incu-
Figure 2. Erectile function upon cavernous nerve electro
ICP/MAP. *P .05. (B) Representative ICP recordings per
rection in diabetic rats, indicative of an inability to maintain
avernous nerve with a duration of 50 s.bated at 4°C with mouse anti-rat endothelial cell antigen-1
UROLOGY 78 (2), 2011(RECA1; AbD Serotec, Raleigh, NC), rabbit anti-Collagen IV
(Abcam, Inc., Cambridge, MA), or rabbit anti-neuronal nitric
oxide synthase (nNOS; Santa Cruz Biotechnology, Santa Cruz,
CA) 1:400 in 3% horse serum/PBS. Control tissue sections were
similarly prepared except no primary antibody was added. After
rinses with PBS, the sections were incubated with Alexa-488 or
Alexa-594 conjugated goat anti-rabbit or goat anti-mouse sec-
ondary antibodies (Invitrogen, Carlsbad, CA). After rinsing of
the slides in PBS, tissue sections were stained for F-actin. Slides
were therefore incubated with Alexa-488-conjugated phalloi-
din (1:500 in 1% BSA, Invitrogen) for 20 minutes at room
temperature, followed by incubation with 4=,6-diamidino-2-
phenylindole (for nuclear staining, 1 mg/mL, Sigma-Aldrich,
St. Louis, MO). Slides were coverslipped with glycerol 50% in
water. Collagen content was analyzed using Masson’s trichrome
staining method.
Digital Analysis of Sections
Three midpenile tissue sections per animal were included for
statistical analysis. Slides were photographed and recorded us-
ing a Retiga 1300 digital camera (QImaging, Surrey, Canada)
attached to a Nikon E300 microscope (Nikon Instruments,
Melville, NY). Computerized histomorphometric analysis was
performed using Image-Pro plus 5.1 software (Media Cybernet-
ics, Bethesda, MD).
Statistical Analysis
The results were analyzed using MedCalc version 11.0.0.0
(MedCalc software, Mariakerke, Belgium). To test the differ-
ence between means, Student’s t-test was used. Results were
considered statistically significant if P .05. Data are shown as
mean  standard error of the mean (SEM).
RESULTS
Establishment of Type 2 Diabetes Mellitus
Body weight and postprandial blood glucose were measured
weekly. Although control rats gradually gained weight,
DM2 rats showed little changes in body weight until week
11, when it started to decline (Fig. 1A). All animals in
the DM2 group developed diabetes as indicated by blood
glucose levels of 300 mg/dL one week after injection of
STZ (Fig. 1B). Overt clinical features in DM2 rats in-
ulation. (A) The effects of induction of DM2 on ratio of
p. Note the spiky appearance of the plateau phase of the
tion. The red bar represents an electrical stimulation of thestim
grou
ereccluded development of cataract and suppurative balani-
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Figure 3. Changes in the endothelium and dorsal penile nerves in the diabetic rat penis. (A) Representative images of
endothelial lining of sinusoids. Rat penis was stained with Alexa-488-conjugated phalloidin and with Alexa-594-conjugated
anti-RECA1 antibody. Original magnification1000. Note the “patchy” appearance of the endothelial lining in diabetic penile
sinusoids, whereas the endothelial lining is continuous in normal rats. (B) Representative images of rat penile dorsal
nerves. Rat penis was stained with Alexa-488-conjugated phalloidin and with Alexa-594-conjugated anti-nNOS antibody.
Original magnification 200. Note the significant decrease of nNOS positive nerve fibers, which are located mainly in the
periphery of the dorsal nerve (arrows). (C) Quantification of RECA1-staining in pixels/HPF. *P .001. (D) Quantification of
nNOS staining in dorsal penile nerves. *P .001.
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eFigure 4. Smooth muscle and extracellular matrix in the corpus cavernosum. (A) Representative pictures of the rat corpus
cavernosum stained with Masson’s trichrome. Red color represents mainly smooth muscle, blue stains collagen fibers.
Original magnification 40. (B) Histomorphometric analysis of the content of the corpus cavernosum. Upper and middle
anel: collagen content and smooth muscle content in percentage of total intratunical area; lower panel: ratio smooth
uscle (%)/collagen (%). *P .05. (C) Rat penis was stained with Alexa-488-conjugated phalloidin and with Alexa-594-
onjugated anticollagen-IV antibody. Original magnification 400. Representative high-power images of smooth muscle
undles lining a cavernosal sinusoid(*). Upper panel: normal rat; lower panel: diabetic rat. Note the somewhat denser
xpression of the sinusoidal subendothelial basement membrane in the diabetic rat sinus (arrowhead).
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ctis. The latter was treated with nontraumatic drainage
and rinsing of the preputium and a short course of oral
antibiotics. No animals died during the course of the
study.
Because decreased sensitivity to insulin is a hallmark of
DM2, insulin resistance was tested at weeks 6 and 12
after injection of STZ. The results show that DM2 rats
lacked response to insulin challenge (Fig. 1C, 1D).
Serum Analysis
Animals in the DM2 group showed significant increases
in levels of serum triglycerides, total cholesterol, and low-
and high-density lipoproteins (LDL and HDL). Testos-
terone and insulin levels were significantly lower com-
pared with controls (Fig. 1E, 1F).
Assessment of Erectile Function
Induction of DM2 consistently resulted in ED as illustrated
by a significant decline in ICP/MAP ratio upon CN elec-
trostimulation in the STZ and HFD-treated group com-
pared with control animals (Fig. 2).
Histomorphometric Analysis
The cavernous endothelium of DM2 rats lost continuity
and had a “patchy” appearance (Fig. 3A). Expression of
RECA1 was significantly decreased compared with age-
matched controls (P .001, Fig. 3C). Furthermore, sig-
nificant decreases in nNOS content of the dorsal penile
nerves were noted in DM2 rats (Fig. 3B, 3D).
Masson’s trichrome stain showed that smooth muscle
content was significantly lower in the corpus cavernosum
of diabetic rats (P  .012). Collagen content was in-
creased but this difference was not significant (P  .04).
Thus, the ratio of smooth muscle over collagen content
was decreased in diabetic rats (Fig. 4A, 4B). There were
no major morphologic alterations in cavernous smooth
muscle after the induction of diabetes. However, the
subendothelial basement membrane appeared slightly
denser in the diabetic animals (Fig. 4C).
COMMENT
In this study we confirmed the development of ED in a
rat model of DM2 induced by HFD feeding combined
with low-dose STZ injection. Chiou et al previously
published the development of moderate erectile function
impairment as early as 6 weeks after induction of diabetes
in rats treated with HFD and low-dose STZ.9 The authors
emonstrated altered protein expression in the corpus
avernosum. Because their study lacks data on insulin
etabolism, it is unclear whether the proposed altera-
ions in protein expression are related to an early (hy-
erinsulinemia) or advanced stage (hypoinsulinemia) of
M2. Most critical, however, is a lack of immunohisto-
orphometric analysis of the erectile apparatus. Indeed,
n the literature, high-quality morphologic data on erec-
ile tissue in any DM2 rat model is rather scarce.
The induction of DM2 used in this study closely re-
476.e6embles the natural history of the disease. The two weeks
f HFD feeding produces insulin resistance syndrome in
he absence of hyperglycemia, a condition similar to
rediabetes in humans.11 After two weeks of HFD, injec-
ions with low-dose STZ produced frank hyperglycemia
nd thus mimicked the decline in secretory capacity of
ancreatic -cells.11 The persistent hyperglycemia fur-
ther damages the pancreatic -cells through gluco(Lipo)
toxicity, oxidative stress, amyloid deposition, and an in-
crease in circulating advanced end-products of glycation
(AGEs). These factors cause islet inflammation and ul-
timately lead to apoptosis of -cells, resulting in hypoin-
sulinemia in the advanced stage of DM2.12 In addition,
our model showed several hallmarks of DM2. First, as
early as 6 weeks after injection of STZ, the treated rats
did not show a significant drop in glucose levels upon
injection of a fixed dose of insulin. This characteristic
persisted into the later stage of the disease at 12 weeks
and represents decreased insulin sensitivity, or insulin
resistance. Second, by 12 weeks after STZ injections,
endogenous insulin production had decreased dramati-
cally, indicating the presence of -cell failure. Third, the
rats showed profound hyperlipidemia, hypercholesterol-
emia, and hypogonadism, which are metabolic changes
commonly seen in human DM2 patients and that, aside
from the persistent hyperglycemia, might contribute to
erectile and general tissue damage.13
Previously, ED in DM2 has been studied in genetic rat
models, such as the Zucker rat, the BBZ/WOR, and the
Otsuka Long-Evans Tokushima Fatty rat.2,3 Although
hese genetic models develop characteristics of DM2
imilar to those in humans, costs can be as high as 10-fold
f those of Sprague-Dawley or Wistar rats. More impor-
antly, these models unanimously are characterized by
besity and therefore fail to represent the rather large
opulation of nonobese individuals who are metaboli-
ally abnormal but nevertheless exposed to an increased
isk of diabetic and cardiovascular complications, such as
D. In contrast, our STZ-HFD model does represent
hese patients because it is phenotypically lean while
ossessing the metabolic characteristics of DM2, includ-
ng hyperlipidemia and hypogonadism. Thus, whereas the
ocus in the Western world remains on the more preva-
ent obese patients, our lean DM2 model is better posi-
ioned to address the needs of the nonobese DM2 popu-
ation, which is estimated to constitute 42% of DM2
ases worldwide.14
A decrease of endothelial function in the erectile
tissue has been repeatedly described in the aforemen-
tioned DM2 genetic rat models.5,7,15,16 However, little is
known about whether the endothelial dysfunction is as-
sociated with morphologic changes in the cavernous en-
dothelium. In the present study, we observed a lower
expression level of RECA1 in the corpus cavernosum of
DM2 rats compared with their age-matched nondiabetic
controls. By using a novel phalloidin-based method for
counterstaining of the cavernous smooth muscle, we
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with high accuracy. A striking microanatomical
change resulting in disruption of the endothelial bar-
rier had taken place in the diabetic animals. The
endothelium had a “patchy” appearance, whereas con-
trol rats had an intact endothelial lining of the cav-
ernous sinuses. These observed changes may be attrib-
utable to a combination of persisting hyperglycemia,
resulting in increased levels of reactive oxygen species,
which in combination with increased LDL levels, re-
sults in pathologic inflammatory changes, as previously
described in the vascular endothelium.17-21 In addi-
tion, diabetic rats showed profound hypogonadism,
possibly contributing to a decreased endothelial integ-
rity.
Reduced expression of nNOS in the penis of diabetic
rats is a common finding in models for both chemically
induced type 1 and genetic type 2 diabetes.6,16,22,23 Fur-
hermore, a previous publication showed with Western
lot analysis that the amount of nNOS protein in HDF-
TZ rats was significantly lower than in controls.9 In the
present study, we confirmed this finding immunohisto-
chemically and showed a striking decrease in nNOS
expression in the dorsal penile nerves of diabetic rats. A
reduced nNOS expression results in a decrease in endog-
enous NO availability from the cavernous nerve endings
and thereby impairs erectile function upon cavernous
nerve stimulation. The reduced expression of nNOS,
combined with a putative loss of endothelium-derived
NO may explain the high rates of nonresponders to
PDE5-inhibitor therapy in advanced diabetic ED.
Various groups have described a decrease in corpus
cavernosum smooth muscle content in DM2 rat mod-
els.24 This decrease has been ascribed to an increased
mooth muscle apoptotic rate and has further been linked
o decreased circulating testosterone levels.25 Moreover,
increased deposition of collagen in the erectile tissue was
found in diabetic animals and has been linked to in-
creased levels of transforming growth factor–beta in the
diabetic penis.24,26,27 In line with previous studies in
ther diabetic rat models, we found a decreased smooth
uscle/total collagen ratio in the corpus cavernosum.
owever, detailed analysis of the smooth muscle mor-
hology using phalloidin staining did not find signifi-
ant morphologic alterations other than changes in
mooth muscle content identified by trichrome stain.
decreased smooth muscle/total collagen ratio may
ontribute to ED by decreasing the expandability of
he sinusoids upon passive filling with blood, thereby
esulting in veno-occlusive dysfunction.28 Indeed, this
tructure-related dysfunction is reflected in the spiky
hape of the plateau phase of the erection in the ICP
ecording, as evidenced in Figure 2B.
Collagen-IV is an extracellular matrix molecule that is
xpressed in the subendothelial basement membrane.
his protein further occurs in the basal lamina surround-
ng each individual smooth muscle cell in the corpus
UROLOGY 78 (2), 2011avernosum (Fig. 4C). It plays an important role in
aintaining the contractile capacity of the smooth mus-
le bundle, and changes in its expression have been
dentified in diabetes-associated diseases, such as diabetic
ephropathy.29,30 In the present study we found that,
although collagen-IV expression in the subendothelial
basement membrane was somewhat higher in the DM2
group than in the control group (Fig. 4C), there was no
difference in overall collagen-IV expression in the penis
(data not shown).
Inherent to the concept of a pilot-study, the number of
animals included in both groups was relatively low. De-
spite these small group sizes, significant changes in both
glucose and lipid metabolism, erectile biology, and penile
morphology were observed. These findings are promising
for the use of this model for further research, including
the investigation of novel treatment options for ED in
diabetes. A larger-scale investigation toward the patho-
physiological mechanisms involved in the development
of ED is needed to further validate this animal model.
Furthermore, insights in the role that altered collagen-IV
metabolism plays in diabetic ED is needed and has re-
cently been initiated in our laboratory.
CONCLUSIONS
Treatment of rats with low-dose STZ injection in com-
bination with a HFD resulted in the establishment of a
lean model of DM2 that mimicked the natural progres-
sion of the disease in humans. ED was present at 12 weeks
after induction of diabetes and was histomorphometri-
cally characterized by decreased nNOS expression, loss of
endothelial integrity, and a decreased smooth muscle/
collagen ratio. As such, this rat model is a more afford-
able alternative to the commonly used genetic rat models
for the study of DM2-associated ED.
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